Jupiter Life Line Hospitals Limited has informed the Exchange about Transcript
JLHL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jupiter Life Line Hospitals shared its Q4 and FY25 earnings call transcript, reporting FY25 total income of INR 1,261.5 crores (+17.5% YoY), EBITDA of INR 296.6 crores with a 23.5% margin, and PAT of INR 193.5 crores at a 15.3% margin. Q4 income rose 12.1% YoY to INR 326.7 crores with EBITDA of INR 78.3 crores (23.9% margin), while PAT dipped 0.9% YoY due to higher depreciation. The company highlighted progress on its 2,500-bed Western India target, with Indore expansion (78 new beds added in Jan 2025), ongoing Thane restructuring, and upcoming Dombivli (Q1 FY27) and Pune greenfield projects (~INR 500 crore capex, 500 beds). Management raised INR 350 crore debt at the listed entity and INR 250 crore at the Indore subsidiary, taking the total cash position to ~INR 600 crore to fund both greenfield and potential acquisition opportunities. ARPOB grew 10.4% to INR 60,600 and average occupancy improved 150 bps to 65.3%.
Strong FY25 performance with healthy margin expansion and a 10%+ ARPOB increase signals solid operational execution. The INR 600 crore cash position and stated openness to acquisitions could act as a growth catalyst, though near-term margin pressure from new hospital ramp-ups and higher depreciation is already visible in the flat Q4 PAT.